Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firmonertinib + pemetrexed + carboplatin + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Allist Pharmaceuticals, Inc.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Firmonertinib + pemetrexed + carboplatin + bevacizumab is an investigational combination regimen being evaluated for the first-line treatment of locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). The regimen combines **firmonertinib** (a third-generation EGFR tyrosine kinase inhibitor), **pemetrexed** (an antifolate chemotherapy agent), **carboplatin** (a platinum-based DNA-crosslinking agent), and **bevacizumab** (a monoclonal antibody targeting VEGF-A). This multi-modal approach is designed to simultaneously inhibit oncogenic driver signaling, disrupt cellular metabolism and DNA integrity, and suppress tumor angiogenesis. It is currently being studied in a Phase 2 clinical trial utilizing a ctDNA-guided adaptive treatment strategy to optimize therapy based on molecular residual disease (MRD) status.
02
Targets
ABCB1 (P-glycoprotein)ABCG2 (Breast cancer resistance protein)DHFR (Dihydrofolate reductase)DNAEGFR (Epidermal growth factor receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)GART (GAR transformylase)
Beyond the preview
Go deeper on firmonertinib + pemetrexed + carboplatin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firmonertinib + pemetrexed + carboplatin + bevacizumab.